Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Thermo Fisher Scientific Inc. (TMO) Marc Casper Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

CVS Health

Sarepta Therapeutics

Tenet Healthcare

Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60. Tenet is a Dallas-based healthcare provider organization operating a collection of hospitals (65) and many outpatient facilities, including ambulatory surgery centers, urgent care centers, freestanding imaging centers, freestanding emergency rooms/micro-hospitals, and physician practices across the United States.

Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today

WALTHAM, Mass., Jan. 6, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment Solutions, a new subscription-based offering that bundles instrument and equipment procurement with consumables,...

Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions

WALTHAM, Mass., Jan. 5, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2020 before the market opens on Monday, February 1, 2021, and will hold a...

Thermo Fisher Scientific to Hold Earnings Conference Call on Monday, February 1, 2021

Avantor Inc.

Becton, Dickinson and Co.

Johnson & Johnson

Moderna

Pfizer

West Pharmaceutical Services

The Covid-19 vaccine rally isn't just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.

7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Thermo Fisher (TMO)

WALTHAM, Mass., Dec. 31, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it has completed the acquisition of Phitonex, Inc., a Durham, North Carolina-based company that has pioneered a spectral dye platform for high-resolution biology...

Thermo Fisher Scientific Acquires Programmable Dye Platform Pioneer Phitonex

DuPont de Nemours

Intel

Arrowhead Pharmaceuticals

Onto Innovation

Veeco Instruments

Seven nanotech stocks to buy have the potential to reward investors as innovation in the sector accelerates. The post 7 Nanotech Stocks To Buy With Huge Returns in Store appeared first on InvestorPlace.

7 Nanotech Stocks To Buy With Huge Returns in Store

AbbVie

Abbott Labs

Eli Lilly

Novo Nordisk

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.

5 Health Care Stocks Outperforming the Benchmark

Thermo Fisher Scientific saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 94 the day before. The post Thermo Fisher Scientific Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.

Thermo Fisher Scientific Joins Elite List Of Stocks With 95-Plus Composite Rating

Adaptive Biotechnologies

BridgeBio Pharma Inc

Boston Scientific

Centene

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Centene Corp. (NYSE:CNC), BridgeBio Pharma Inc. (NASDAQ:BBIO), Boston Scientific Corp. (NYSE:BSX) and Thermo Fisher Scientific Inc. (NYSE:TMO). This week, Halvorsen revealed a slight reduction to his Adaptive Biotechnologies position according to GuruFocus Real-Time Picks, which is also a Premium feature.

Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter

Hologic

IDEXX Laboratories

ResMed

Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

5 MedTech Stocks That Have Outperformed the Industry in 2020

Owens & Minor

QuidelOrtho Corp

Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

Thermo Fisher (TMO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Thermo Fisher (TMO)

There are now over 60 million COVID-19 cases worldwide, and they're continuing to rise. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) gave the world hope as their candidates showed 90% efficacy.

3 COVID Stocks Not To Neglect

Activision Blizzard

Lennar

Parker-Hannifin

TTEC Holdings

These dividend growth stocks have superior fundamentals, making them quality and promising investments for the long term.

5 Top-Ranked Stocks With Solid Dividend Growth to Bet On

The company is perfectly placed to take advantage of newfound structural growth within the healthcare industry. Covid-19 has provided a strong tailwind to earnings in 2020 and this looks set to be repeated in 2021.

Thermo Fisher Scientific: A Brave New World (Of Healthcare Growth)

Salesforce

Fiserv

Five Below

Zoom Video

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Salesforce and Five Below

Top Wall Street analysts back these stocks as market notches record highs

Labcorp Holdings Inc

To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.

3 Growth Stocks to Tap the COVID-Driven Shift in MedTech

The demand for cold storage and transportation could make these stocks scorching-hot buys.

2 Stocks to Buy With Multiple COVID-19 Vaccines in Sight

Best Buy

Herbalife

Lowe's

Lam Research

Medifast

Growth names have been at the forefront of this new COVID world, and have kept society not only afloat, but growing and transitioning to this new normal. Nobody knows exactly what the future will hold, but our AI algorithms have identified standout growth stocks via our rating system.

Top Growth Stocks For December

PerkinElmer

Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.

4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success

The IBD SmartSelect Composite Rating for Thermo Fisher Scientific rose from 94 to 98 Tuesday. The post Thermo Fisher Scientific Stock Is Rising With High Composite Rating appeared first on Investor's Business Daily.

Thermo Fisher Scientific Stock Is Rising With High Composite Rating

The IBD SmartSelect Composite Rating for Thermo Fisher Scientific rose from 94 to 98 Tuesday. The post Stocks With Rising Composite Ratings: Thermo Fisher Scientific appeared first on Investor's Business Daily.

Stocks With Rising Composite Ratings: Thermo Fisher Scientific

Mastercard

Medtronic

The S&P 500 saw its trailing 12-month real earnings per share (EPS) grow by approximately 1.4% on average every year over the past five years. The index's share price ($3,629.65 as of Wednesday) rose by nearly 74% over the past five years through Nov. 25.

News for Thermo Fisher Scientific Stock (TMO)